Author |
N |
Method |
Treatment |
Endpoint |
Comment |
Terrazino |
125 |
PCR/DNA |
45-50.4 Gy 5-FU or 5-FU+LV or 5-FU+Oxa or 5-FU+ carboplatin |
TRG |
No correlation |
Bertolini |
91 |
IHC |
50 Gy 5-FU |
TRG; TNM downstaging; OS/DFS |
No correlation |
Spindler |
60 |
PCR/DNA |
65 Gy UFT+LV |
TRG |
TS 2R/2R associated with tumor regression |
Jakob |
22 |
PCR/RNA |
50.4 Gy 5-FU |
TRG |
Low TS expression associated with tumor regression |
Stoehlmacher |
40 |
PCR/DNA; PCR/RNA |
50.4 Gy 5-FU |
TRG |
TS 3-UTR 6 bp deletion slightly associated with tumor response |
Negri |
57 |
IHC |
40-45 Gy +/- 5-FU + oxa |
pCR |
High TS expression associated with higher rate of response |
Kikuchi |
60 |
IHC |
45 Gy Irinotecan |
TRG |
Higher TS expression associated with better response |
Carlomagno |
46 |
IHC |
45 Gy Capecitabine + Oxa |
TRG |
Low TS expression assocoated with low response |
Hur |
44 |
IHC; PCR/DNA |
45 Gy 5-FU |
TRG; TNM downstaging |
Low-expression genotypes associated with TNM downstaging; no correlation with TRG |
Paez |
51 |
PCR/DNA |
45 Gy 5-FU |
TRG; TNM downstaging |
Genotipe 3R/3R associated with tumor response |
TS: Thymidylate synthase; PCR: polymerase chain reaction; IHC:inmunohistochemistry; 5-FU:5-fluoruracil; LV:leucovorin; Oxa:oxaliplatin; UFT:Uftotal; TRG: tumor regression grade; OS: overall survival; DFS: disease-free survival; TNM tumor node metastasis staging; pCR: pathological complete response |